Market Newsdesk

STMicroelectronics introduces first automotive safety combination sensors for mass-market applications

• Cohesive sensor platform accelerates development of advanced active and passive safety systems
• First mass-market products launched following the integration of NXP’s sensors division earlier this year

Geneva, Switzerland, October 26, 2026 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, has announced a set of automotive sensors that enable vehicle brands to extend advanced safety and driver-assistance features across categories from premium to mass-market, broadening access to state-of-the-art protection.

Combining multi-axis accelerometers and gyroscopes (angular rate sensors) in a single package, ST’s new sensors offer a unified platform for OEMs and Tier-1 suppliers to build active and passive safety systems that meet stringent automotive quality, reliability, and safety requirements. The devices address use-cases ranging from crash protection, rollover detection, and airbag deployment to vehicle stability controls and radar beam stabilization.

These are the first products launched in the mass market following ST’s acquisition of the NXP automotive and industrial MEMS sensors business in early 2026, a move completed to expand its own MEMS sensors capabilities. ST’s experience in automotive sensing reflects its commitment to guaranteeing product availability for at least 15 years, allowing companies to minimize lifecycle and redesign risks while investing confidently in new programs.

“As a cohesive sensor set suited to multiple safety functions, these devices simplify system architecture, accelerate development, and increase flexibility to scale features and performance,” said Simone Ferri, Executive Vice President, MEMS Sub-Group, STMicroelectronics. “Strengthened by our longevity commitment and global support infrastructure, these are the first automotive safety combination sensors ready for mass-market deployment, accelerating the move to active safety.”

Omdia has commented on the market opportunities for inertial sensing in Advanced Driver Assistance Systems (ADAS). Nora Houlihan, Senior Research Analyst at Omdia, said, “Thanks to ADAS, inertial measurement units (IMUs) are expected to grow at 17.7% CAGR (2025-30). As automotive manufacturers approach higher levels of autonomy there will be a significant increase in IMU-powered MEMS sensors for acceleration and motion detection.”

Further technical information

ST’s combination sensors integrate a multi-axis accelerometer and gyroscope in a single ISO 26262 compliant device with full internal diagnostics. All sensors support SafeSPI, the standard serial peripheral interface for automotive safety, that enables independent monitoring of sensor data.

The new sensors comprise:

• NCS1012BAEP, with z-axis (yaw) angular rate sensor and xy low g acceleration sensor.
• NCS1012CAEP, with x-axis (roll) angular rate sensor and yz low g acceleration sensor.
• NCS1012EAEP, with x-axis (roll) angular rate sensor and xy medium g acceleration sensor.
• NCS10135AEP with z-axis (yaw) angular rate sensor and xyz low g acceleration sensor.

The integrated angular rate sensors have a full-scale range of ±125 dps, ±250 dps or ±350 dps and feature low offset with minimal drift over the automotive temperature range (−40°C to +105°C). A low-pass filter is integrated, with 3dB frequency options of 12.5Hz to 400Hz, as well as an optional single-pole high-pass filter with fast startup.

The low g acceleration sensors feature a nominal full-scale range from ±1.50 g to ±34 g, while the medium g acceleration sensors have nominal full-scale range from ±15.5 g to ±150 g, featuring an independent signal chain to minimize noise, low offset with low drift over the automotive temperature range, and an integrated low-pass filter.

The four new sensors are in production now, in 24-pin QFN 6mm x 6mm x 1.90mm packages, with wettable flanks meeting automotive-industry optical inspection compatibility requirements.

Contact your local ST sales office for sample requests and pricing.

Please visit www.st.com/mems-for-automotive for more information.

About STMicroelectronics

At ST, we are 49,000 creators and makers of semiconductor technologies mastering the semiconductor supply chain with state-of-the-art manufacturing facilities. An integrated device manufacturer, we work with more than 200,000 customers and thousands of partners to design and build products, solutions, and ecosystems that address their challenges and opportunities, and the need to support a more sustainable world. Our technologies enable smarter mobility, more efficient power and energy management, and the wide-scale deployment of cloud-connected autonomous things. We are on track to be carbon neutral in all direct and indirect emissions (scopes 1 and 2), product transportation, business travel, and employee commuting emissions (our scope 3 focus), and to achieve our 100% renewable electricity sourcing goal by the end of 2027. Further information can be found at www.st.com.

For further information, please contact:

INVESTOR RELATIONS

Jérôme Ramel
EVP Corporate Development & Integrated External Communication
Tel: +41 22 929 59 20
[email protected]

MEDIA RELATIONS

Alexis Breton
Group VP Corporate External Communications
Tel: +33 6 59 16 79 08
[email protected]

Attachment

• P4796D — Oct 26 2026 — MEMS Safety Sensors_FINAL FOR PUBLICATION

Andrew Murray joins as Senior Vice President to deepen Nasdaq’s Financial Technology client partnerships across Asia-Pacific as the region enters a defining era of market evolution

Bob McCooey, Vice Chairman and Head of International Listings, relocates to Singapore to broaden access to global capital for the region’s companies and investors

SINGAPORE, Oct. 25, 2026 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced the appointment of Andrew Murray as Senior Vice President, Financial Technology, Asia-Pacific, strengthening its senior presence in one of the world’s most dynamic regions. Based in Singapore, Murray will deepen Nasdaq’s Financial Technology client partnerships and accelerate business growth across Asia-Pacific, supporting financial institutions as they deliver on their technology and transformation priorities. His appointment follows the relocation to Singapore of Bob McCooey, Vice Chairman and Head of International Listings, a move that enhances Nasdaq’s engagement with the region’s companies and their access to global capital.

These developments position Nasdaq to help advance the region’s technology and capital markets ambitions.

“Asia-Pacific is entering one of the most significant cycles of innovation and market evolution in decades, driven by AI, data and the move toward always-on, globally connected markets,” said Valerie Bannert-Thurner, Executive Vice President and Chief Revenue Officer, Financial Technology at Nasdaq. “Andrew’s strong track record of helping financial institutions solve complex technology challenges will be invaluable as our clients navigate this rapidly changing landscape. Alongside Bob and our teams across the region, we are committed to being a trusted, long-term partner to Asia-Pacific’s market ecosystems.”

Murray brings more than three decades of experience leading teams and building long-term client partnerships at financial technology companies serving treasury, trading, corporate banking and capital markets clients. Most recently, he served as a leader in International Banking and Payments at FIS, where he supported clients across the full banking and payments value chain. His career includes senior international leadership positions at FIS in Banking & Markets and Post-Trade Solutions, as well as previous experience at Calypso Technology (now part of Nasdaq), SunGard, Wall Street Systems and Deutsche Bank.

“Asia-Pacific’s ambition is reshaping the global economy, and the region’s companies and investors increasingly seek access to deep, global pools of capital to fuel that growth,” said Bob McCooey, Vice Chairman and Head of International Listings at Nasdaq. “Strengthening our presence on the ground will allow us to work more closely with the region’s companies, investors and market participants, and deepen our role as a long-term partner across Asia-Pacific. Together, we can bring the full breadth of Nasdaq to support the innovation and economic growth that define this region.”

McCooey’s relocation underscores Nasdaq’s commitment to broadening access to capital and supporting the development of companies and economies across Asia-Pacific. With more than two decades at Nasdaq, McCooey has partnered with many of the region’s most innovative companies on their journeys to the global capital markets. Being based in Singapore will facilitate closer collaboration with clients, partners and local market ecosystems.

Basing two additional senior leaders in Singapore also reflects Nasdaq’s enduring commitment to Asia-Pacific. As the region’s markets become more connected, continuous and technology-driven, Nasdaq will continue to partner with clients, exchanges and market ecosystems to strengthen the trusted infrastructure that supports capital formation and long-term economic growth.

Notes to editors

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading technology platform that powers the world’s economies. We architect the world’s most modern markets, power the innovation economy, and build trust in the financial system. We empower economic opportunity by designing and deploying the technology, data, and advanced analytics that enable our clients to capture opportunities, navigate risk, and strengthen resilience. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.

Media Contacts: 

Sophie Sophaon; +852 6305 7060; [email protected]

Andrew Hughes; +44 (0)7443 100896; [email protected]

-NDAQG-

LOS ANGELES, Oct. 25, 2026 (GLOBE NEWSWIRE) — Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Flotek Industries, Inc. (“Flotek” or “the Company”) (NYSE: FTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of FTK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: August 3, 2026 to August 17, 2026

DEADLINE: October 26, 2026

If you are a shareholder who suffered a loss, click here to participate.

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Flotek’s power generation project with the Puerto Rico Electric Power Authority (“PREPA”) suffered from credible doubts about PREPA’s financial capacity and organizational ability to complete the work. The Company suffered from risks related to the revenue from its PREPA contract. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Flotek, investors suffered damages.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Join the case to recover your losses

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.        

CONTACT:

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE:

Schall, Brown & Schwartz LLP

LAKE MARY, Fla., Oct. 25, 2026 (GLOBE NEWSWIRE) — OpenWorld, Inc. (NASDAQ: OPNW) (“OpenWorld” or the “Company”), a blockchain innovation company advancing real-world asset tokenization, today confirmed that its planned dual listing on Figure’s On-chain Public Equity Network (“Figure OPEN”) remains on track to go live in the fourth quarter of 2026.

OpenWorld expects to be among the first Nasdaq-listed companies to bring its public equity on-chain, giving institutional and retail investors a new way to hold and trade shares of a U.S. exchange-listed company without leaving the regulatory boundaries of the existing securities framework.

The update follows stockholder approval on October 16, 2026 of the Company’s Amended and Restated Articles of Incorporation (“Restated Articles”), which authorizes a new class of Blockchain Common Stock. As disclosed in the Company’s Current Report on Form 8-K filed on October 16, 2026. This is the corporate mechanism required to bring OpenWorld’s equity onto Figure OPEN.

No New Shares – One Company, Two Ways to Trade

The Figure OPEN listing does not involve the issuance of any new shares and will not raise capital. OpenWorld’s Blockchain Common Stock will serve as a blockchain-native version of the Company’s existing Nasdaq-listed shares, giving stockholders the choice of holding and trading OPNW shares on Nasdaq or on Figure OPEN. Blockchain Common Stock is designed to settle in real time, rather than on the conventional T+1 cycle, and to trade around the clock. The Company’s total number of outstanding shares will not increase.

“Bringing OPNW on-chain has been part of our vision since day one, and we remain on track to execute this vision with Figure OPEN later this quarter,” said Matthew Shaw, Chief Executive Officer and Chairman of OpenWorld. “Bringing our shares on-chain through Figure OPEN provides our existing stockholders with greater choice, without any dilution, as markets increasingly move 24/7 through blockchain rails. When we go live on Figure OPEN, our shareholders can trade on Nasdaq as they always have or hold the same ownership as a blockchain-native share with faster settlement and extended trading access. We believe this is where public markets are heading, and we intend to be at the front of it.”

Delivering on the Dual-Listing Plan

As announced on October 1, 2026, OpenWorld is pursuing a dual listing on Figure OPEN, building on its previously announced agreement with Figure Technology Solutions, Inc. (NASDAQ: FIGR) to offer a digitally native share class. With stockholder approval secured, OpenWorld expects the Figure OPEN listing to be live later this quarter.

The Figure OPEN listing is designed to complement, not replace, the Company’s Nasdaq listing. OpenWorld remains subject to the same SEC reporting requirements, corporate governance standards and investor protections.

Compliant Transfer Agent to Simplify the Dual Structure

To make moving between the two formats simple for stockholders, OpenWorld has appointed Vinyl Equity, Inc., an SEC-registered transfer agent equipped to maintain records for both traditional and blockchain-based shares. The transfer agent will support stockholders who wish to hold their shares in either form. OpenWorld will provide information on how stockholders can access the blockchain-based shares.

Charter Amendments Approved

On September 30, 2026, OpenWorld’s Board of Directors approved the Restated Articles and submitted them to stockholders. On October 16, 2026, stockholders holding approximately 57.57% of the Company’s issued and outstanding common stock, a majority of its outstanding voting power, approved the Restated Articles by written consent under Section 78.320 of the Nevada Revised Statutes. The amendments provide for:

• The authorization of 500,000,000 shares of Blockchain Common Stock, par value $0.001 per share, as a “blank check” class issuable in one or more series.
• An express election permitting the Company to make distributions that would otherwise be prohibited by NRS 78.288(2)(b).

Upon effectiveness, OpenWorld’s authorized capital stock will consist of 675,000,000 shares of Common Stock, 500,000,000 shares of Blockchain Common Stock and 75,000,000 shares of Preferred Stock, each with a par value of $0.001 per share. Authorized shares represent the maximum the Company may issue and do not change the number of shares outstanding. The Restated Articles will become effective upon filing with the Nevada Secretary of State following the expiration of the applicable notice period under Rule 14c-2 under the Securities Exchange Act of 1934, as amended, following the mailing of OpenWorld’s definitive Information Statement on Schedule 14C to its stockholders, which is expected to begin on October 26, 2026.

About OpenWorld

OpenWorld, Inc. (NASDAQ: OPNW) is a digital assets and blockchain technology company. Through its OpenWorld Enterprise platform, the Company provides financial structuring and blockchain infrastructure for the issuance and distribution of tokenized real-world assets to institutional and retail investors. To learn more, visit openworld.dev.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the timing of filing and effectiveness of the Company’s Restated Articles, the timing of the Company’s definitive Information Statement on Schedule 14C being mailed to the Company’s stockholder, the timing and expected benefits of the Company’s listing on Figure OPEN, the issuance and characteristics of Blockchain Common Stock, and the services of the Company’s transfer agent. Words such as “believe,” “expects,” “intends,” “planned,” “will,” and similar expressions identify forward-looking statements. These statements are subject to risks and uncertainties, including regulatory approvals, market conditions and technology readiness, that could cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the date of this release. OpenWorld undertakes no obligation to update them except as required by law. Additional risks are described in the Company’s filings with the SEC.

Contacts

Investors:
[email protected]

Media:
[email protected]

NMS Equity Transfer Agent: Vinyl Equity, Inc., 1-888-80-VINYL (84695)

Blockchain Equity Transfer Agent:

Figure Equity Solutions, Inc.,

[email protected]

Source:


Form 8-K filed with the SEC

.

Prior announcements

:

October 1 Nasdaq listing

;

Figure agreement

.

LAKE MARY, Fla., Oct. 25, 2026 (GLOBE NEWSWIRE) — OpenWorld, Inc. (NASDAQ: OPNW) (“OpenWorld” or the “Company”), a blockchain innovation company advancing real-world asset tokenization, today confirmed that its planned dual listing on Figure’s On-chain Public Equity Network (“Figure OPEN”) remains on track to go live in the fourth quarter of 2026.

OpenWorld expects to be among the first Nasdaq-listed companies to bring its public equity on-chain, giving institutional and retail investors a new way to hold and trade shares of a U.S. exchange-listed company without leaving the regulatory boundaries of the existing securities framework.

The update follows stockholder approval on October 16, 2026 of the Company’s Amended and Restated Articles of Incorporation (“Restated Articles”), which authorizes a new class of Blockchain Common Stock. As disclosed in the Company’s Current Report on Form 8-K filed on October 16, 2026. This is the corporate mechanism required to bring OpenWorld’s equity onto Figure OPEN

No New Shares – One Company, Two Ways to Trade

The Figure OPEN listing does not involve the issuance of any new shares and will not raise capital. OpenWorld’s Blockchain Common Stock will serve as a blockchain-native version of the Company’s existing Nasdaq-listed shares, giving stockholders the choice of holding and trading OPNW shares on Nasdaq or on Figure OPEN. Blockchain Common Stock is designed to settle in real time, rather than on the conventional T+1 cycle, and to trade around the clock. The Company’s total number of outstanding shares will not increase.

“Bringing OPNW on-chain has been part of our vision since day one, and we remain on track to execute this vision with Figure OPEN later this quarter,” said Matthew Shaw, Chief Executive Officer and Chairman of OpenWorld. “Bringing our shares on-chain through Figure OPEN provides our existing stockholders with greater choice, without any dilution, as markets increasingly move 24/7 through blockchain rails. When we go live on Figure OPEN, our shareholders can trade on Nasdaq as they always have or hold the same ownership as a blockchain-native share with faster settlement and extended trading access. We believe this is where public markets are heading, and we intend to be at the front of it.”

Delivering on the Dual-Listing Plan

As announced on October 1, 2026, OpenWorld is pursuing a dual listing on Figure OPEN, building on its previously announced agreement with Figure Technology Solutions, Inc. (NASDAQ: FIGR) to offer a digitally native share class. With stockholder approval secured, OpenWorld expects the Figure OPEN listing to be live later this quarter.

The Figure OPEN listing is designed to complement, not replace, the Company’s Nasdaq listing. OpenWorld remains subject to the same SEC reporting requirements, corporate governance standards and investor protections.

Compliant Transfer Agent to Simplify the Dual Structure

To make moving between the two formats simple for stockholders, OpenWorld has appointed Vinyl Equity, Inc., an SEC-registered transfer agent equipped to maintain records for both traditional and blockchain-based shares. The transfer agent will support stockholders who wish to hold their shares in either form. OpenWorld will provide information on how stockholders can access the blockchain-based shares.

Charter Amendments Approved

On September 30, 2026, OpenWorld’s Board of Directors approved the Restated Articles and submitted them to stockholders. On October 16, 2026, stockholders holding approximately 57.57% of the Company’s issued and outstanding common stock, a majority of its outstanding voting power, approved the Restated Articles by written consent under Section 78.320 of the Nevada Revised Statutes. The amendments provide for:

• The authorization of 500,000,000 shares of Blockchain Common Stock, par value $0.001 per share, as a “blank check” class issuable in one or more series.
• An express election permitting the Company to make distributions that would otherwise be prohibited by NRS 78.288(2)(b).

Upon effectiveness, OpenWorld’s authorized capital stock will consist of 675,000,000 shares of Common Stock, 500,000,000 shares of Blockchain Common Stock and 75,000,000 shares of Preferred Stock, each with a par value of $0.001 per share. Authorized shares represent the maximum the Company may issue and do not change the number of shares outstanding. The Restated Articles will become effective upon filing with the Nevada Secretary of State following the expiration of the applicable notice period under Rule 14c-2 under the Securities Exchange Act of 1934, as amended, following the mailing of OpenWorld’s definitive Information Statement on Schedule 14C to its stockholders, which is expected to begin on October 26, 2026.

About OpenWorld

OpenWorld, Inc. (NASDAQ: OPNW) is a digital assets and blockchain technology company. Through its OpenWorld Enterprise platform, the Company provides financial structuring and blockchain infrastructure for the issuance and distribution of tokenized real-world assets to institutional and retail investors. To learn more, visit openworld.dev.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the timing of filing and effectiveness of the Company’s Restated Articles, the timing of the Company’s definitive Information Statement on Schedule 14C being mailed to the Company’s stockholder, the timing and expected benefits of the Company’s listing on Figure OPEN, the issuance and characteristics of Blockchain Common Stock, and the services of the Company’s transfer agent. Words such as “believe,” “expects,” “intends,” “planned,” “will,” and similar expressions identify forward-looking statements. These statements are subject to risks and uncertainties, including regulatory approvals, market conditions and technology readiness, that could cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the date of this release. OpenWorld undertakes no obligation to update them except as required by law. Additional risks are described in the Company’s filings with the SEC.

Contacts

Investors:
[email protected]   

Media:
[email protected] 

NMS Equity Transfer Agent: Vinyl Equity, Inc., 1-888-80-VINYL (84695)

Blockchain Equity Transfer Agent:

Figure Equity Solutions, Inc., [email protected] 

Source:

Form 8-K filed with the SEC.

Prior announcements

: October 1 Nasdaq listing; Figure agreement.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1881bca4-3fc3-4014-824c-36b701b0b84e

— ORPATHYS

^®

plus TAGRISSO

^®

reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

^®

—

— 
ORPATHYS

^®

plus TAGRISSO

^®

extended median OS by nearly 5 months —

— SAFFRON is the first global Phase III trial to show significant progression-free and overall survival benefit in this setting —

— 
Establishes ORPATHYS

^®

plus TAGRISSO

^®

as a
n important
targeted strategy to address MET-driven resistance following
progression on prior
EGFR TKI treatment
—

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 25, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces positive results from the SAFFRON global Phase III trial. ORPATHYS^® (savolitinib) plus TAGRISSO^® (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (“PFS”) and overall survival (“OS”) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (“EGFRm”) non-small cell lung cancer (“NSCLC”). Patients in the trial had tumors with high levels of MET overexpression or amplification and had progressed on prior treatment with TAGRISSO^®.

These results have been presented during the Presidential Symposium at the European Society for Medical Oncology (“ESMO”) Congress in Madrid, Spain (abstract #LBA6).¹ They were also simultaneously published in The New England Journal of Medicine 2026. Featuring prominently on oncology’s premier stage and in a flagship journal underscores the pivotal nature of the SAFFRON trial in redefining the treatment paradigms for MET-driven EGFRm NSCLC. The data validate ORPATHYS^® combined with TAGRISSO^® as a landmark, all-oral strategy to address the major unmet need of MET-driven resistance after third-generation epidermal growth factor receptor (“EGFR”) tyrosine kinase inhibitor (“TKI”) therapy.

Results showed ORPATHYS^® plus TAGRISSO^® reduced the risk of disease progression or death by 45% compared to chemotherapy (based on a PFS hazard ratio [“HR”] of 0.55; 95% confidence interval [“CI”] 0.42-0.72; p<0.001). Median PFS as assessed by blinded independent central review (“BICR”) was 7.6 months for ORPATHYS^® plus TAGRISSO^® versus 5.4 months for the comparator arm. An estimated 36% of patients treated with the combination were progression-free at one year compared to 10% in the comparator arm. Importantly, the PFS benefit observed was consistent across all prespecified subgroups, including patients whose tumor had MET-overexpression or MET-amplification.

Results for the key secondary endpoint of OS showed ORPATHYS^® plus TAGRISSO^® reduced the risk of death by 32% versus chemotherapy (OS HR 0.68; 95% CI 0.50-0.91; p=0.010). ORPATHYS^® plus TAGRISSO^® extended median OS by 4.9 months versus the comparator arm (17.8 versus 12.9 months). An estimated 70% of patients treated with the combination were alive at one year compared to 53% in the comparator arm.

Professor Shun Lu, Director of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine and global leading principal investigator of the trial, said: “These results have the potential to establish a new global standard of care for the third of patients with EGFR-mutated non-small cell lung cancer experiencing MET-driven resistance after osimertinib. There are currently no well-tolerated, oral, biomarker-directed treatment options to address this frequent driver of disease progression. Savolitinib plus osimertinib significantly extended median overall survival by nearly five months in this later-line setting, establishing a new clinical benchmark and reinforcing the critical need for MET testing to guide patient care.”

Mr Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED, said: “These data from SAFFRON mark a decisive step forward in targeting MET-driven resistance — a longstanding challenge in EGFR-mutated lung cancer. Precision inhibition with ORPATHYS^® alongside TAGRISSO^® offers a meaningful, all-oral option for patients with disease progression. We are delighted to see that our partnership with AstraZeneca continues to deliver impactful innovations that have the potential to redefine standard of care and improve outcomes for patients globally.”

Dr
Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “These data show combining ORPATHYS^® with backbone therapy TAGRISSO^® directly addresses MET-driven resistance while maintaining EGFR suppression, building on the established efficacy, safety and central nervous system protection of TAGRISSO^®. With the potential to become the first biomarker-directed, all-oral treatment option in this setting, this combination further strengthens our leadership in EGFR-mutated lung cancer and reflects our strategy of matching the right therapy to the underlying drivers of disease at every stage.”

Summary of PFS and OS results: SAFFRON

ⁱ

	ORPATHYS ® + TAGRISSO ® (n=171)	Chemotherapy (n=167)
PFS by BICR: Full Analysis Set (FAS)
Number of patients with event, n (%)	117 (68.4)	113 (67.7)
Median PFS (95% CI) (in months)	7.6 (5.6-9.7)	5.4 (4.2-5.8)
HR (95% CI)	0.55 (0.42-0.72)
p-value	p<0.001
PFS rate at 12 months (%)	36	10
OS: FAS
Number of deaths, n (%)	87 (50.9)	93 (55.7)
Median OS (95% CI) (in months)	17.8 (15.6-23.7)	12.9 (10.6-16.8)
HR (95% CI)	0.68 (0.50-0.91)
p-value	p=0.010
OS rate at 12 months (%)	70	53
PFS by BICR: MET-overexpressed analysis set
Number of patients, n	127	118
Number of patients with event, n (%)	77 (60.6)	80 (67.8)
Median PFS (95% CI) (in months)	8.5 (5.7-11.1)	5.6 (4.4-6.7)
HR (95% CI)	0.51 (0.37-0.71)
p-value	p<0.001
PFS rate at 12 months (%)	40	11
PFS by BICR: MET-amplified analysis set ii
Number of patients, n	129	116
Number of patients with event, n (%)	89 (68.9)	79 (68.1)
Median PFS (95% CI) (in months)	7.64 (5.6-9.7)	4.2 (3.1-5.5)
HR (95% CI)	0.487 (0.35-0.66)
PFS rate at 12 months (%)	33	8
i  OS and PFS data cut-off was 6 July 2026.  ii No formal statistical testing was carried out for the MET-amplified analysis set

The safety profile for ORPATHYS^® plus TAGRISSO^® was manageable and consistent with the known profiles of each medicine, and there were no new safety concerns. Grade 3 or higher treatment-emergent adverse events from all causes occurred in 64% of patients treated with ORPATHYS^® plus TAGRISSO^® and 63% of patients in the comparator arm. Median total duration of treatment exposure was more than twice as long for ORPATHYS^® plus TAGRISSO^® (8.5 months) compared with the comparator arm (3.5 months).

Based on the SAFFRON Phase III trial results, a New Drug Application (“NDA”) for ORPATHYS^® plus TAGRISSO^® were submitted to the US Food and Drug Administration for the treatment of patients with locally advanced or metastatic NSCLC whose tumors have high levels of MET overexpression or amplification and who had disease progression on or after an EGFR-TKI therapy. An NDA submission in Europe and Japan is also progressing as planned. ORPATHYS^® plus TAGRISSO^® is approved in China for patients with locally advanced or metastatic EGFRm-positive non-squamous NSCLC with MET amplification after disease progression on EGFR TKI therapy based on the SACHI Phase III trial.

Results from the SANOVO Phase III trial evaluating ORPATHYS^® plus TAGRISSO^® in treatment-naïve patients in China with EGFRm locally advanced or metastatic NSCLC and MET overexpression will be presented during a Proffered Paper session at the ESMO Congress (abstract #LBA69). ²

ORPATHYS^® is being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.

About NSCLC and MET aberrations

Lung cancer is the leading cause of cancer death globally, accounting for almost one in four (23%) cancer deaths.^3,4 Lung cancer is broadly split into NSCLC and small cell lung cancer, with 80-85% of patients diagnosed with NSCLC.⁵ Approximately 75% of NSCLC patients are diagnosed with advanced disease.⁶ Additionally, about 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia, have EGFRm NSCLC.^​7

MET is a tyrosine kinase receptor that has an essential role in normal cell development.⁸ MET overexpression or amplification can lead to tumor growth and the metastatic progression of cancer cells.^8,9 Approximately one in three patients’ tumors will develop high levels of MET overexpression or amplification (IHC3+>90% and FISH10+) after progression on a third-generation EGFR-TKI.¹⁰

About SAFFRON

SAFFRON is a randomized, open-label, multi-center, global Phase III trial studying the efficacy of ORPATHYS^® (300 mg twice daily) added to TAGRISSO^® (80 mg once daily) versus doublet platinum-based chemotherapy in 338 patients with EGFRm, locally advanced or metastatic NSCLC with MET overexpression or amplification whose disease progressed following first- or second-line treatment with TAGRISSO^®. The trial enrolled patients in 230 centers across 29 countries in North America, Europe, South America and Asia. The primary endpoint is PFS and key secondary endpoint includes OS.

Patients were prospectively selected for SAFFRON using the high MET level cut-offs identified in the SAVANNAH Phase II trial. ​In SAVANNAH, MET overexpression or amplification levels were determined by two tests: immunohistochemistry (IHC), which detects if cancer cells have a particular protein or marker on their surface, and fluorescence in situ hybridization (FISH), which detects a specific DNA sequence from cancer cells.

About ORPATHYS

^®

ORPATHYS^® (savolitinib) is an oral, potent and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression.

ORPATHYS^® is approved in China for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, representing the first selective MET inhibitor approved in China. ORPATHYS^® also received a conditional approval in China for the treatment of adult patients with locally advanced or metastatic gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments. ORPATHYS^® in combination with TAGRISSO^® is approved in China for patients with locally advanced or metastatic EGFR mutation-positive non-squamous NSCLC with MET amplification after disease progression on EGFR TKI therapy based on the SACHI Phase III trial. The combination was also granted a temporary authorization in Switzerland for the treatment of patients with locally advanced or metastatic EGFRm NSCLC and high levels of MET overexpression or amplification who progressed on prior treatment with TAGRISSO^®. This was based on results from the global SAVANNAH Phase II trial. The global, randomized, SAFFRON Phase III trial in the same treatment setting comparing the combination with doublet platinum-based chemotherapy reported positive high-level results, demonstrating a statistically significant and clinically meaningful improvement in PFS and OS in August 2026.

About TAGRISSO

^®

TAGRISSO^® (osimertinib) is a third-generation, irreversible EGFR TKI with proven clinical activity in NSCLC, including the treatment of central nervous system metastases.

TAGRISSO^® is approved as monotherapy in more than 120 countries including the US, EU, China and Japan. Approved indications include for first-line treatment of patients with locally advanced or metastatic EGFRm NSCLC, locally advanced or metastatic EGFR T790M mutation-positive NSCLC, adjuvant treatment of early-stage EGFRm NSCLC and locally advanced, unresectable NSCLC following platinum-based chemoradiation therapy. TAGRISSO^® is also approved in combination with chemotherapy in more than 80 countries, including the US, EU, China and Japan, for first-line treatment of patients with locally advanced or metastatic EGFRm NSCLC.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of ORPATHYS

^®

, the further clinical development for ORPATHYS

^®

, its expectations as to whether any studies on ORPATHYS

^®

would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of ORPATHYS

^®

, including as a combination therapy, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of ORPATHYS

^®

for a targeted indication; the sufficiency of funding; HUTCHMED’s and AstraZeneca’s ability to successfully develop and commercialize ORPATHYS

^®

. In addition, as certain studies rely on the use of other drug products such as TAGRISSO

^®

as combination therapeutics with ORPATHYS

^®

, such risks and uncertainties include assumptions regarding the safety, efficacy, supply and continued regulatory approval of these therapeutics. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries	+852 2121 8200 / [email protected]
Media Enquiries
FTI Consulting –	+44 20 3727 1030 / [email protected]
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / [email protected]
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
Deutsche Numis	Joint Broker
Duncan Monteith / Ramin Naji	+44 20 7545 8000

 

REFERENCES
1	Lu S, et al. Osimertinib [osi] + savolitinib [savo] vs platinum–pemetrexed [plat–pem] in EGFRm MET-overexpressed [OE] and/or -amplified [AMP] advanced NSCLC post-osi: SAFFRON Phase [Ph] 3 primary results. Presented in a Proffered Paper session during Presidential Symposium II the European Society for Medical Oncology Congress 2026, 25 October at 16:45 CET.
2	Wu YL, et al. Savolitinib or Placebo Combined with Osimertinib in Treatment-Naïve Advanced NSCLC with EGFR Mutation and MET Overexpression: Results from the Phase 3 SANOVO Study. Presented at the European Society for Medical Oncology Congress 2026, 26 October at 08:30 CET.
3	World Health Organization. International Agency for Research on Cancer. Lung Fact Sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf. Accessed October 2026.
4	World Health Organization. International Agency for Research on Cancer. All Cancers Fact Sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/39-all-cancers-fact-sheet.pdf. Accessed October 2026.
5	American Cancer Society. What Is Lung Cancer? Available at: https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html. Accessed August 2026.
6	Chen HJ, et al. Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI. Medicine. 2021;100(6):e24688.
7	Gao X, et al. The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. Expert Rev Anticancer Ther. 2016;16(4):383-390.
8	Uchikawa E, et al. Structural basis of the activation of c-MET receptor. Nat Commun. 2021;12(4074)
9	Wang Q, et al. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol. 2019;63.
10	De Marinis F, et al. Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study. Ann Oncol. 2025;36(8):920-933.